regorafenib

Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.

Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.

Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Regorafenib (BAY 73-4506) mesylate is an orally active multi-target receptor tyrosine kinase inhibitor, inhibiting VEGFR1 2 3 (IC50=13 4.2 46 nM), PDGFRβ (IC50: 22 nM), Kit (IC50: 7 nM), RET (IC50: 1.5 nM), and Raf-1 (IC50: 2.5 nM), with potent anti-tumor and anti-angiogenic effects.

Regorafenib-13C-d3 the 13C and deuterated compound of Regorafenib. Regorafenib has a CAS number of 755037-03-7. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5 2.5 4.2 7 13 22 nM for RET C-RAF VEGFR2 c-Kit VEGFR1 PDGFRβ).

Regorafenib D3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor inhibitor of tyrosine kinase.

Regorafenib-13C-d3 N-Oxide the 13C and deuterated compound of Regorafenib N-Oxide. Regorafenib N-Oxide has a CAS number of 835621-11-9. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1 2 3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13 4.2 46, 1.5, 22, 7, and 2.5 nM).

N-Desmethyl Regorafenib N-oxide, an active metabolite of the multi-kinase inhibitor regorafenib, originates through the action of the cytochrome P450 (CYP) isoform CYP3A4. This compound demonstrates efficacy in vitro by inhibiting key enzymes such as VEGFR2, Tie2, c-Kit, and B-RAF, and it exhibits tumor growth inhibition in HT-29 and MDA-MB-231 mouse xenograft models at a dosage of 1 mg/kg.

BAY-751098 is a bio-active chemical.

USP28-IN-2 is a selective USP28 inhibitor (IC50 = 0.3 μM), demonstrating high specificity compared to USP2, USP7, USP8, USP9x, UCHL3, and UCHL5. This compound exhibits cytotoxic effects on cancer cells and induces the degradation of c-Myc via the ubiquitin-proteasome pathway. Additionally, USP28-IN-2 reduces ankyrin-1 2 levels in vitro and potentiates the responsiveness of colorectal cancer cells to Regorafenib [1].

Regorafénib N-oxyde M2 is an active metabolite of Regorafenib, a multi-target inhibitor for VEGFR1 2 3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13 4.2 46, 1.5, 22, 7, and 2.5 nM).